Financials in GBp. Standardized financial statements.
A compact view of how N4 Pharma Plc turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £7,282 | £1,953 | £0 | £0 | £0 | £0 | £0 | £0 | £1.16M | £0 |
| Revenue Growth? | +272.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% |
| Cost of Revenue? | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £934,000 | £0 |
| Gross Profit? | £7,282 | £1,953 | £0 | £0 | £0 | £0 | £0 | £0 | £221,000 | £0 |
| Gross Margin? | +100.0% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +19.1% | 0.0% |
| Operating Expenses? | £1.17M | £1.43M | £1.19M | £1.84M | £1.56M | £947,340 | £1.42M | £616,527 | £249,000 | £160,000 |
| Operating Income? | -£1.22M | -£1.43M | -£1.19M | -£1.84M | -£1.56M | -£947,000 | -£1.42M | -£726,000 | -£28,000 | -£160,000 |
| EBITDA? | -£1.22M | -£1.33M | -£1.19M | -£1.84M | -£1.56M | -£947,000 | -£1.42M | -£1.92M | -£22,000 | £70,000 |
| Income Before Tax | -£1.22M | -£1.43M | -£1.19M | -£1.84M | -£1.57M | -£949,000 | -£1.39M | -£1.93M | -£22,000 | -£164,000 |
| Income Tax Expense | -£101,000 | -£148,000 | -£164,000 | -£298,000 | -£262,000 | -£72,352 | -£206,000 | -£89,874 | £0 | -£13,000 |
| Net Income? | -£1.06M | -£1.27M | -£1.03M | -£1.54M | -£1.30M | -£876,000 | -£1.19M | -£1.84M | -£22,000 | -£1.05M |
| EPS? | £-0.00 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.03 | £-0.00 | £-0.09 |
| Diluted EPS? | £-0.00 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.01 | £-0.03 | £-0.00 | £-0.09 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality